Pancreatic Neuroendocrine Tumor Clinical Trial
Official title:
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
PRIMARY OBJECTIVE: I. To evaluate recurrence-free survival (RFS) in participants with resected pancreatic neuroendocrine tumors (pNETs) randomized to treatment with capecitabine + temozolomide (CAPTEM) compared to observation only. SECONDARY OBJECTIVES: I. To evaluate overall survival (OS) in participants randomized to treatment with CAPTEM compared to observation only. II. To evaluate the safety and tolerability of CAPTEM compared to observation only. BANKING OBJECTIVE: I. To bank specimens for future correlative studies. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14 and temozolomide PO once daily (QD) on days 10-14. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo surveillance with no active treatment. After completion of study treatment, patients are followed up every 6 months for 3 years and then annually until 5 years from randomization. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05566093 -
EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors
|
N/A | |
Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
Recruiting |
NCT05568017 -
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
|
Phase 2 | |
Not yet recruiting |
NCT06024343 -
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction
|
N/A | |
Recruiting |
NCT03891784 -
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT03204019 -
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
|
Phase 2 | |
Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
Recruiting |
NCT05997056 -
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
|
Phase 2 | |
Not yet recruiting |
NCT06158516 -
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT00576680 -
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05610826 -
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03074513 -
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
|
Phase 2 | |
Completed |
NCT03967951 -
CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
|
||
Completed |
NCT01024387 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Not yet recruiting |
NCT03435770 -
Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms
|
N/A | |
Recruiting |
NCT04134832 -
Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
|
||
Recruiting |
NCT05554744 -
EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors
|
N/A | |
Completed |
NCT02159989 -
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Not yet recruiting |
NCT06406387 -
ATRX/DAXX in EUS-FNB Specimens of Pan-NETs
|